Business
TME Pharma Announces That Nominated CEO Plans to Increase His Shareholding
BERLIN, May 05, 2025--Regulatory News: TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces today that Diede van den Ouden plans to enlarge his stake in the company by buying shares on the market.
About this update from Tme Pharma N.v.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1000,"height":313,"url":"https://media.zenfs.com/en/business-wire.com/5d0e5619da01c844ec20f125a0a47c86"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/y9Yjwu9K7MNK_TnhnS248g--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwMDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/5d0e5619da01c844ec20f125a0a47c86","width":960,"height":300},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/Q3.0Jfo2m1tbqTMipvsxUQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIwMDA7aD02MjY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/5d0e5619da01c844ec20f125a0a47c86","width":1000,"height":313}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Diede van den Ouden has disclosed plans for initial share purchases to become a more significant shareholder in TME Pharma prior to his nomination for appointment as CEO at the upcoming AGM in June 2025","length":202,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":202,"olType":false},{"type":"text","content":" ","length":6,"tagName":"p"},{"type":"text","content":"BERLIN, May 05, 2025--(BUSINESS WIRE)--Regulatory News:","length":55,"tagName":"p"},{"type":"text","content":"TME Pharma N.V. (Euronext Growth Paris: ALTME), a clinical-stage biotechnology company focused on developing novel therapies for treatment of cancer by targeting the tumor microenvironment (TME), announces today that Diede van den Ouden plans to enlarge his stake in the company by buying shares on the market.","length":310,"tagName":"p"},{"type":"text","content":""I want to commit myself to the success of the company and align my interests with those of other shareholders," said Diede van den Ouden. "I am instructing these share purchases now since I expect to become an insider again very soon in order to discuss participating in a non-dilutive financing with the current CEO."","length":339,"tagName":"p"},{"type":"text","content":"Mr. van den Ouden has given a set of instructions to his financial institution to purchase initially up to 1.5 million shares on the market with a maximum of 25% of daily volume. He will share all transactions carried out by his financial institution on his behalf with the company on a daily basis and the company will post ...